Scandion Oncology A/S reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was DKK 10.15 million compared to DKK 25.07 million a year ago. Basic loss per share from continuing operations was DKK 0.25 compared to DKK 0.62 a year ago. Diluted loss per share from continuing operations was DKK 0.25 compared to DKK 0.62 a year ago.
For the nine months, net loss was DKK 28.22 million compared to DKK 61.01 million a year ago. Basic loss per share from continuing operations was DKK 0.69 compared to DKK 1.5 a year ago. Diluted loss per share from continuing operations was DKK 0.69 compared to DKK 1.5 a year ago.